Exec tasked with helping Lonza address "Visp challenge" to step down

By Gareth Macdonald

- Last updated on GMT

Exec tasked with helping Lonza address "Visp challenge" to step down
Beat In-Albon, the man tasked with improving profitability at Lonza’s manufacturing site in Visp, Switzerland, will step down at the end of the year.

The Swiss life sciences supplier announced that In-Albon would relinquish his role as COO for its specialty ingredients business today, explaining that he would continue to be involved in “special projects​” and report directly to CEO, Richard Ridinger.

In-Albon joined Lonza in 2012​ and was given the job of improving profitability at the company’s manufacturing facility in Visp. The site had struggled to complete in recent years as a result of high running costs, international competition and the strong Swiss franc.

Spokeswoman Constance Ward told us “Beat In-Albon had a significant impact on the successful implementation of our Visp Challenge program and helped to make the site more robust, competitive and cost effective, which had a positive effect on Lonza’s profitability​.”

In-Albon’s job became even more of a challenge in January when the Swiss National Bank (SNB) discontinued the​ CHF1.20 per Euro exchange rate it imposed in 2011.

The surprise move and the consequent currency fluctuations saw shares in Lonza and fellow Swiss firm SGS – In-Albon’s previous employers – slump.

In-Albon’s departure does not mean the challenges Lonza faces at Visp are over according to Ward.

Big industrial sites such as Visp in the middle of Europe have the constant task of reviewing their portfolios and maintaining their competiveness by bringing higher-margin activities to the sites.

She added that: “Continuous improvement is an everyday task in such an environment, and Beat had a strong influence on this mindset​.”

In-Albon will be replaced by Sven Abend, currently Chief Strategy Officer and member of the Executive Committee.

Abend will take over as head of Lonza’s specialty ingredients business on January 1 next year.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars